Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals, a specialty pharmaceutical company, has announced that Rapaflo, the company's new, uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia, is available for patients by prescription.
Subscribe to our email newsletter
The product label provides that one 8mg Rapaflo capsule be taken once daily with a meal. Stocking efforts have ensured the product will be available immediately by prescription at retail pharmacies nationwide, the company said.
In addition to Rapaflo, Watson will soon launch Gelnique, the first and only topical gel for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Watson also has submitted a new drug application for a six-month formulation of Trelstar, a luteinizing hormone releasing hormone agonist for the palliative treatment of advanced prostate cancer. Watson anticipates that the FDA will take action on this application in the third quarter of 2009.
Paul Bisaro, president and CEO of Watson, said: “The launch of Rapaflo is an important milestone and, coupled with the forthcoming launch of Gelnique, marks the continued strength and expansion of Watson’s brand division and urology franchise. We are confident that the proven rapid efficacy and safety of Rapaflo will provide benign prostatic hyperplasia patients and their physicians an important treatment option.”